Page last updated: 2024-09-02

fingolimod hydrochloride and Graves Disease

fingolimod hydrochloride has been researched along with Graves Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Banga, JP; Bechrakis, NE; Berchner-Pfannschmidt, U; Diaz-Cano, S; Eckstein, A; Hansen, W; Hendgen-Cotta, UB; Hose, M; Michel, L; Plöhn, S; Schlüter, A	1

Other Studies

1 other study(ies) available for fingolimod hydrochloride and Graves Disease

Article	Year
Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor. Thyroid : official journal of the American Thyroid Association, 2019, Volume: 29, Issue:9 Topics: Animals; Autoantibodies; CD8-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Graves Disease; Graves Ophthalmopathy; Mice; Mice, Inbred BALB C; Receptors, Thyrotropin; T-Lymphocytes, Regulatory	2019

Article

Year

Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor.

Thyroid : official journal of the American Thyroid Association, 2019, Volume: 29, Issue:9

Topics: Animals; Autoantibodies; CD8-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Graves Disease; Graves Ophthalmopathy; Mice; Mice, Inbred BALB C; Receptors, Thyrotropin; T-Lymphocytes, Regulatory

2019